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A B S T R A C T
Preclinical and clinical evidence suggests pro-inflammatory cytokines might play an important role in the
neurobiology of schizophrenia and stress-related psychiatric disorders. Interleukin-18 (IL-18) is a member of the
IL-1 family of cytokines and it is widely expressed in brain regions involved in emotional regulation. Since IL-18
involvement in the neurobiology of mental illnesses, including schizophrenia, remains unknown, this work
aimed at investigating the behavior of IL-18 null mice (KO) in different preclinical models: 1. the prepulse
inhibition test (PPI), which provides an operational measure of sensorimotor gating and schizophrenic-like
phenotypes; 2. amphetamine-induced hyperlocomotion, a model predictive of antipsychotic activity; 3. resident-
intruder test, a model predictive of aggressive behavior. Furthermore, the animals were submitted to models
used to assess depressive- and anxiety-like behavior. IL-18KO mice showed impaired baseline PPI response,
which was attenuated by D-amphetamine at a dose that did not modify PPI response in wild-type (WT) mice,
suggesting a hypodopaminergic prefrontal cortex function in those mice. D-Amphetamine, however, induced
hyperlocomotion in IL-18KO mice compared to their WT counterparts, suggesting hyperdopaminergic activity in
the midbrain. Moreover, IL-18KO mice presented increased basal levels of IL-1β levels in the hippocampus and
TNF-α in the prefrontal cortex, suggesting an overcompensation of IL-18 absence by increased levels of other
proinflammatory cytokines. Although no alteration was observed in the forced swimming or in the elevated plus
maze tests in naïve IL-18KO mice, these mice presented anxiogenic-like behavior after exposure to repeated
forced swimming stress. In conclusion, deletion of the IL-18 gene resembled features similar to symptoms ob-
served in schizophrenia (positive and cognitive symptoms, aggressive behavior), in addition to increased sus-
ceptibility to stress. The IL-18KO model, therefore, could provide new insights into how changes in brain im-
munological homeostasis induce behavioral changes related to psychiatric disorders, such as schizophrenia.
1. Introduction
Over the last two decades, several studies have suggested an im-
portant bidirectional interaction between psychological stress and the
immune system (Glaser and Kiecolt-Glaser, 2005; Kusnecov and Rabin,
1994; Segerstrom and Miller, 2004). In fact, pro-inflammatory
cytokines, such as interleukin 1 (IL-1), IL-6, IL-18 and tumor necrosis
factor alpha (TNF-α) are constitutively expressed in different limbic
brain regions of the rodent brain (Goshen and Yirmiya, 2009; Pickering
et al., 2005; Stellwagen and Malenka, 2006; Tonelli and Postolache,
2005) and the administration of pro-inflammatory cytokines produces a
core of endocrine, neurochemical, and behavioral changes that are
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similar to those produced by stress exposure (Goshen and Yirmiya,
2009; Kwon et al., 2008; Madrigal et al., 2002; O'Connor et al., 2003).
On the other hand, inhibiting the activity of pro-inflammatory cyto-
kines in animals often attenuates stress-induced consequences (Goshen
et al., 2007), thus suggesting pro-inflammatory cytokines play a pro-
minent role in the modulation of neuroendocrine, behavioral and
emotional responses to stress (Goshen and Yirmiya, 2009).
Altered levels of pro-inflammatory cytokines (TNF-α, IL-1β and IL-
6) are also found in the serum and in the brain of psychiatric patients
(Anisman and Merali, 2002; Levine et al., 1999; Licinio and Wong,
1999; Maes, 1995, 1999; Penninx et al., 2003; Tuglu et al., 2003) and
chronic treatment with psychotropic medication, specially anti-
depressants and antipsychotics, can correct such imbalances. Moreover,
the use of interferon α (IFN-α) produce significant changes in brain
metabolism as well as psychotic and depressive symptoms in humans
(Capuron et al., 2007; Drozdz et al., 2007). Altogether, these studies
highlight the possibility that cytokines could contribute to the devel-
opment of stress-related mental illnesses, such as anxiety, depression,
and schizophrenia (Papanicolaou et al., 1998; Schiepers et al., 2005;
Yirmiya, 2000).
Interleukine-18 (IL-18) is a pleiotropic cytokine (Nakanishi et al.,
2001) member of the IL-1 family. IL-18 shares with IL-1β the same
converting enzyme (caspase 1) that cleaves its precursor pro-IL-18 to
yield the active IL-18 (Okamura et al., 1995). This cytokine and its
receptors are constitutively expressed in astrocytes, microglia, neurons
and ependymal cells of different brain areas of the rodent brain, in-
cluding limbic regions (Alboni et al., 2009; Culhane et al., 1998;
Felderhoff-Mueser et al., 2005; Wheeler et al., 2000). Moreover, IL-18
can regulate neurotransmitter release (Kanno et al., 2004), modulate
neuronal excitability (Kanno et al., 2004), stress-induced microglial
activation (Sugama et al., 2007), and interfere with plastic events in the
CNS (Curran and O'Connor, 2001). Despite that, IL-18 involvement in
the neurobiology of psychiatric disorders remains poorly investigated.
Schizophrenic patients have increased levels of IL-18 in the serum
(Monji et al., 2009; Tanaka et al., 2000; Zhang et al., 2013) and poly-
morphisms in IL-18 gene have been related to specific clinical mani-
festations of schizophrenia, such as perception disorder and aggression,
but were not directly connected with the risk of disease (Liu et al.,
2011). Higher plasma levels of IL-18 are observed in first-episode
psychosis and are positively correlated with cognitive impairments in
chronic schizophrenic patients (Orhan et al., 2017, Wu et al., 2016).
Moreover, IL-18 increase in the chronic phase of schizophrenia is po-
sitively correlated with positive and negative symptoms (Xiu et al.,
2012). Although these recent evidences suggest IL-18 may play an
important role in schizophrenia neurobiology, it is not known how IL-
18 absence would affect behaviors predictive of schizophrenic-like
phenotype. Additionally, there is scarce information about IL-18 in-
volvement in the neurobiology of other mental disorders, such as an-
xiety and depression (Eisener-Dorman et al., 2010; Too et al., 2014;
Yaguchi et al., 2010; Yamamoto et al., 2010),
Based on the aforementioned evidence, the present study aimed at
investigating the behavioral effects induced by IL-18 absence in mice
submitted to preclinical models used to study schizophrenia and stress-
related psychiatric disorders, including: prepulse inhibition (PPI) test;
amphetamine-induced hyperlocomotion; social isolation induced ag-
gression; elevated plus-maze and forced swimming test. Considering
that prepulse inhibition (PPI) disruption possibly reflects the difficulty
of suppressing or filtering excessive information in schizophrenic pa-
tients (Braff et al., 2001; Swerdlow et al., 2008), PPI deficits across
species, has been considered to reflect a schizophrenic-like phenotype
(Swerdlow et al., 2008) and evaluation of this behavior in rodents is
relevant to schizophrenia studies. Moreover, since psychotic patients
release more dopamine after stimulation with amphetamine than
normal individuals, possibly due to increased midbrain dopaminergic
activity (Abi-Dargham et al., 2009), the hyperlocomotion-induced by
amphetamine can be used to investigated increased activity in this
brain region. Aggression and antisocial behavior are aften observed in
schizophrenia and it can be induced by social isolation (Buckley et al.,
2011; Buckley et al., 2004; Serper, 2011; Soyka, 2011). Therefore, we
also investigated if social-isolation induced aggressive behavior would
be altered in IL-18 KO mice. Last, considering the well-known in-
volvement of proinflammatory cytokines in responses evoked by stress
exposure, we also evaluated if IL-18 KO present different behaviors in
the elevated plus maze and forced swimming stress, in addition to in-
creased susceptibility to stress exposure. Finally, we also measured IL-
1β, IL-33, and TNF-α in the medial prefrontal cortex (MPFC), striatum
(ST) and hippocampus (HIP), brain regions that have been associated
with those disorders.
2. Material and methods
2.1. Animals
210 mice were used in this study. This study was conducted in male
recessive homozygous IL-18 deficient (KO) (Balb/c background) and
Balb/c wild-type control mice (9–12 weeks). The IL-18KO mice, a do-
nation from Dr. Foo Liew (University of Glasgow), were generated as
previously described in C57 BL/6 mice and backcrossed to Balb/c for
eight generations (Wei et al., 1999). They were provided by our local
Animal farm facility, and their genetic status was confirmed by PCR
(Wei et al., 1999). After arriving at the Animal Care Unit of the De-
partment of Pharmacology, Medical School of Ribeirao Preto, Uni-
versity of Sao Paulo, animals were housed in groups of 8–10 animals
per cage, in a temperature-controlled room (24 ± 1 °C) under standard
laboratory conditions (12 h light/12 h dark, lights on at 06:30 h) with
free access to food and water. Procedures were conducted in conformity
with the Brazilian Society of Neuroscience and Behavior guidelines for
the care and use of laboratory animals, which comply with interna-
tional laws. All tests were conducted in the light phase.
2.2. Drugs
Powdered D-amphetamine (D-Amph; Sigma) was dissolved in saline
(0.9%). The solutions were prepared immediately before use and in-
jected via intraperitoneal (i.p.) in a volume of 10 ml/kg.
2.3. Experimental procedure
Each behavioral test was performed with independent groups of
animals. WT and KO mice were randomly assigned to the different
experimental groups.
2.4. Behavioral response of IL-18KO mice in Prepulse Inhibition (PPI) Test
and Amphetamine effects
Mice were submitted to the PPI test as described below to record
baseline responses. One week later, animals were resubmitted to the
PPI test after pharmacological challenge with vehicle (10 ml/kg) or
amphetamine (5 mg/kg/i.p.), injected 30 min before test.
PPI of the acoustic startle reflex refers to the reduction in the startle
response magnitude to a startling acoustic ‘pulse’ stimulus when it is
shortly preceded by a weaker non-startling ‘prepulse’ stimulus
(Hoffman and Ison, 1980). Startle response amplitude recording and
PPI were conducted simultaneously in two identical startle systems
(Med Associates, Inc., USA), as previously described (Issy et al., 2009).
The cages were calibrated before the test (adjusted to 150 units) to
ensure equal sensitivity of both response platforms during the test
period. Pulse (pulse alone) was a burst of white noise of 105 dB with a
rise/decay of 5 ms and duration of 20 ms. Prepulse was a pure tone of
80, 85 or 90 dB intensity with frequency of 7 kHz and 10 ms of dura-
tion. The interval between the onset of the prepulse and the pulse was
100 ms and the inter-stimuli interval was of 30 s. Prepulse alone did not
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induce startle responses. PPI test consisted of 64 trials pseudo randomly
divided into eight different categories: pulse alone, prepulse plus pulse,
prepulse alone and null, where no stimulus was presented. Each trial
type was presented at least eight times. The level of PPI was determined
by expressing the prepulse + pulse (PP + P) startle amplitude as a
percentage of pulse-alone (P) startle amplitude [%
PPI = 100 − (100 × PP + P/P)]. Using this formula, a 0% value de-
notes no difference between startle reflex response to the pulse alone
and to the prepulse + pulse and, consequently, no PPI.
2.5. Amphetamine-induced hyperlocomotion
This test was performed in an open field (OF), as previously de-
scribed (Leite et al., 2008). Twenty minutes before the exposure to the
OF, animals received an intraperitoneal injection of vehicle or D-Am-
phetamine (0.625, 1.25, 2.5, 5 or 7.5 mg/kg). The exploratory activity
(distance moved and maximum speed) was videotaped for 5 min and
Any-Maze software (V. 4.5, Stoelting, IL, USA) was employed for be-
havioral analysis. It detects the position of the animal in the open field
and calculates the distance moved and maximum speed.
2.6. Resident-intruder test
The experiments were carried out as previously described, with
some modifications (Lisboa et al., 2007). IL-18KO mice and WT were
isolated during 4 weeks in polycarbonate cages (30 × 20 × 13 cm;
Beiramar). After that period, a non-isolated intruder mouse, from the
same lineage and similar age, was introduced in the resident home cage
for 10 min. Behavior was videotaped and the latency to the first attack
(bite) by the resident, the total time of attacks and the number of at-
tacks were evaluated.
2.7. Exploratory activity
Briefly, the animals were placed in a circular open field (OF) arena
(40 cm in diameter with a 50 cm high Plexiglas wall) for 6 min, as
previously described (Zanelati et al., 2009). The exploratory activity
was videotaped and Any-Maze software (V. 4.5, Stoelting, IL, USA) was
employed for behavioral analysis. It detects the position of the animal
in the open field and calculates the distance moved.
2.8. Forced swimming test
Forced Swimming Test (FST) was performed according to the
method first described by Porsolt and colleagues (Porsolt et al., 1977),
with minor modifications, to access antidepressant-like effects in mice.
Animals were submitted, individually, to the forced swimming in glass
cylinders (height 25 cm, diameter 17 cm) containing 10 cm of water for
6 min, during 5 consecutive days. The total duration of immobility
(characterized by slow movements only to avoid drowning) was vi-
deotaped and measured during the last 4-min period by a trained ob-
server that was blind to the mouse condition on the first, third and fifth
day (Kumar et al., 2010). The water was changed after each trial to
maintain the temperature at 23–25 °C and to prevent the influence of
alarm substances (Abel and Bilitzke, 1990).
2.9. Elevated plus-maze test
The elevated plus-maze (EPM) apparatus consisted of two opposite
wood open arms (34 × 6.5 cm), crossed at right angle by two arms of
the same dimensions enclosed by 15-cm high walls with no roof. The
maze was located 50 cm above the floor. The animals were placed in-
dividually in the center of the maze for free exploration during 5 min.
The behavior was videotaped and the percentages of entries and time
spent in the open arms [100 × open / (open + enclosed)] during the
5 min of test were evaluated by the Any-Maze software (V. 4.5,
Stoelting, IL, USA). Exposure to the EPM was performed in naïve WT
and KO mice or on the first day after 5 days of repeated submission to
the FST and the data were represented as stated above.
2.10. Cytokines measure by ELISA sandwich
Cytokines measure was performed in the brain areas collected from
WT and KO mice that did not undergo any experimental intervention
(naïve). Levels of IL-1β, IL-33 and TNF-α were measured in the medial
prefrontal cortex (MPFC), striatum (ST) and hippocampus (HIP) and
given at pg/μg of total protein. IL-18KO and WT animals were an-
esthetized with 5% chloral hydrate (Sigma; 10 ml/kg), decapitated and
had their brains removed. The structures were dissected and im-
mediately immersed in lyses buffer solution (137 mM NaCl, 20 mM
Tris-HCl, pH 8.0, 10% (v/v) glycerol) containing protease inhibitor
cocktail (10% v/v; Sigma). The tissues were homogenized in this buffer
and centrifuged (10 min, 10,000 rpm, 4 °C).
The supernatants were collected and storage at −70 °C until use.
Briefly, 96 wells plates were incubated with primary antibodies against
IL-1β, TNF-α or IL-33 overnight (kits Duo Set, R&D System). Then the
plates were washed and incubated with BSA 1%, washed again and the
samples or standard curve were added and incubated for 24 h at 4 °C.
After that, the plates were washed and the secondary antibodies were
added and incubated for 1 h at room temperature. Avidine-HRP
(1:5000) was added for 30 min. The plates were washed, color reagent
OPD was added and the plates were kept in the dark in room tem-
perature for 20 min. The enzymatic reaction was stopped with H2SO4
(1 M, 50 μl/well) and the absorbance was determined at 490 nm. The
data were obtained comparing samples values of absorbance with the
standard curve absorbance (Cunha et al., 2000).
2.11. Statistical analysis
Data were analyzed by IBM® SPSS® Statistics software (version 21).
Unpaired t-tests were employed to analyze the aggressive behavior and
data from OF, FST and EPM. Cytokine data did not achieve homo-
geneity of variances and were analyzed by non-parametric analysis
(Mann-Whitney). One-way analysis of variance (ANOVA) was em-
ployed for analysis of the acoustic startle response to pulse alone. The
percentage of PPI was analyzed by repeated measures ANOVA with
prepulse intensity as the repeated measure and the genotype and
treatment as the between-subject factors. Hyperlocomotion induced by
D-Amph was analyzed by two-way ANOVA with the genotype (KO or
WT) and doses of drug as independent factors. In case of significant
interaction between the factors, one-way ANOVA was performed to
compare the different groups, followed by Duncan post hoc test. The
behavioral data were expressed as mean ± SEM. Difference was con-
sidered significant at p≤ 0.05.
3. Results
3.1. Behavior of IL-18KO and WT mice in PPI test and effect of
amphetamine
The statistical analysis showed a significant effect of prepulse in-
tensity (F2,23 = 17.67, p < 0.0001), interaction between prepulse in-
tensity, genotype and treatment and a tendency to a treatment effect
(F1,24 = 3.2, p = 0.08). The baseline (pre-treatment) PPI at prepulse
intensity of 90 dB of IL-18KO mice was lower, which was improved
after D-Amph treatment (p < 0.05, Duncan). At prepulse intensity of
80 dB, although KO mice did not present lower PPI at baseline, the
response was higher after D-Amph (p < 0.05, Duncan; n = 6–8 ani-
mals/group; Fig. 1A).
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3.2. Behavior of IL-18KO and WT mice in the startle response and effect of
amphetamine
There was no difference between baseline startle responses (pulse-
alone, arbitrary units) or startle responses after treatment with am-
phetamine in WT and KO mice (p > 0.05; n = 6–8 animals/group;
Fig. 1B).
3.3. Amphetamine induced hyperlocomotion in IL-18KO and WT mice
In the distance moved (Fig. 2A; n = 5–10 animals/group), there
was a significant effect of genotype (F1,68 = 9.5, p < 0.05), treatment
(F4,68 = 31.6, p < 0.0001) and interaction between factors
(F4,68 = 6.8, p < 0.0001). In the maximum speed (Fig. 2B), there was
only significant effect of treatment (F4,68 = 6.4, p < 0.0001).
D-Amph 5.0 and 7.5 mg/kg significantly increased the distance
moved in WT and KO mice (F9,68 = 16.7, ANOVA p < 0.0001,
Duncan, p < 0.05). Although 7.5 mg/kg induced a greater response
than 5.0 mg/kg in WT mice (Duncan, p < 0.05), this latter dose pro-
moted a higher response in the KO mice. Both D-Amph 5 and 7.5 mg/kg
increased maximum speed in KO mice, whereas only 7.5 mg/kg in-
creased this parameter in WT mice (F9,68 = 3.3, ANOVA between
subjects p < 0.005, Duncan, p < 0.05).
3.4. Evaluation of aggressive and impulsive behavior in the resident-intruder
test
IL-18KO (n = 7–9 animals/group) mice presented increased im-
pulsive and aggressive-behavior expressed by lower latency to the first
bite (t14 = 2.6, p < 0.05; Fig. 3A) and increased total attack time (log
transformation; t13 = 2.3, p < 0.05; Fig. 3C), respectively. There was
also a tendency to increase the number of attacks (log transformation;
t13 = 1.4, p = 0.1; Fig. 3B).
3.5. Behavioral phenotype in the locomotor activity, elevated plus maze
(EPM) and forced swimming (FST) tests
IL-18 KO animals presented a significant reduction in the total
distance moved in the open field test (n = 9/group; IL-18 KO:
t16 = 4.796, p < 0.0005; Fig. 4A). IL-18 naïve KO mice neither pre-
sent any significant difference in behavior evaluated in the EPM com-
pared to naïve WT mice (percentage of entries in the open arms - WT:
9.5 ± 2.4, KO: 11.9 ± 2.6, t= 0.7, d.f. = 20, p > 0.05; percentage
of time in the open arms - WT: 5.1 ± 1.1, KO:4.3 ± 1.1, t = 0.5,
d.f. = 12, p > 0.05; number of entries in the enclosed arms:
t= 1.267, d.f. = 12, p > 0.05; n = 10–12/group; Fig. 4B) nor in the
FST test (WT: 167.9 ± 6.3, KO = 168.2 ± 9.0, t = 0.03, d.f. = 25,
p > 0.05; n = 13–14/group; Fig. 4C).
3.6. Evaluation of behavioral changes in the EPM induced by repeated
forced swim stress
IL-18KO mice did not present significant differences in the im-
mobility time across the repeated forced swimming sessions (t = 1.4,
d.f. = 20, p > 0.05; n = 10–12/group; Fig. 5A). However, when
evaluated one day after the last swimming session, KO mice presented
an anxiogenic-like behavior, represented by decreased percentage of
entries into the open arms (t= 2.8, d.f. = 20, p < 0.05; n = 10–12/
group). There was also a tendency to a decreased percentage of time
spent in these arms (t = 2.0, d.f. = 20, p = 0.06) (Fig. 5B). No effect
was observed in the number of enclosed arms (WT: 14.7 ± 1.5,
KO:19.1 ± 2.7, n = 11–12/group; p > 0.05; data not shown).
3.7. Brain levels of cytokines in IL-18KO and WT mice
In the hippocampus, KO mice (n = 7) presented increased levels of
IL-1β (t= 2.6, d.f. = 13, p < 0.05), but not of TNF-α (p > 0.05) or
IL-33 (p > 0.05), compared to WT mice (n = 9). In the prefrontal
cortex, KO mice (n = 6) presented increased levels of TNF-α (t = 2.5,
d.f. = 12, p < 0.05) and a tendency for increased IL-1β (p = 0.1), but
Fig. 1. A) IL-18 null mice (IL-18KO) performance in the prepulse inhibition (PPI) test and
effect of D-Amphetamine (D-Amph). IL-18KO mice expressed PPI deficit when compared
to their wild type counterparts (WT) at higher prepulse intensity tested (90 dB).
Pretreatment with D-Amph prevented disruption of PPI at 90 dB and increased PPI at
80 dB. All data are expressed as mean ± SEM. *p < 0.05 different from WT and
**p < 0.05 different from KO. Repeated measures, two-way ANOVA and Duncan post-
hoc test. B) Performance of IL-18KO mice in the startle response amplitude in arbitrary
units (AU). There was no difference between WT and KO mice in startle response at
baseline or after D-Amph treatment. Data are expressed as mean ± SEM.
Fig. 2. Effect induced by D-Amph in IL-18KO mice submitted to an open-field. D-Amph
induced hyperlocomotion both in WT and KO mice, represented by increased distance (A)
and maximum speed (B). D-Amph at 5 mg/kg induced the highest effect in KO mice. Data
are expressed as mean ± SEM. Means represented by different letters are significantly
different from each other. Two-way ANOVA and Duncan post-hoc test; n = 9–10/group.
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no alteration in IL-33 level (p > 0.05) compared do WT mice (n = 8).
In the striatum, there was a trend to increased IL-1β levels (p = 0.1) in
the KO mice (n = 7) compared to WT mice (n = 6) (Table 1).
4. Discussion
Our results suggest that IL-18KO mice present behavioral changes
that resemble some features of schizophrenic patients. Despite a dis-
crete impairment of baseline PPI, these animals showed differential
response to amphetamine challenge either in the PPI test or in the lo-
comotor evaluation. In addition, these animals presented increased
aggression, greater sensitivity to repeated stress exposure, and en-
hanced levels of cytokines in limbic regions, such as hippocampus and
prefrontal cortex. On the other hand, IL-18KO mice did not show sig-
nificant behavioral changes when tested in paradigms that are pre-
dictive of anxiety- or depressive-like behaviors.
Polymorphisms in IL-18 gene have been related to specific clinical
manifestations of schizophrenia, such as perception disorder and ag-
gression, but were not directly connected with the risk of disease (Liu
et al., 2011). Altered blood levels of IL-18 have been consistently
described in psychiatric disorders, including schizophrenia. Con-
sidering the increased circulating levels of IL-18 and other cytokines in
schizophrenic patients, it should be expected that IL-18 absence would
rather facilitate PPI, instead of impairing it, as observed herein. In fact,
it has been postulated that inflammatory processes would have a pro-
minent role in the pathogenesis of schizophrenia (Monji et al., 2009).
On the other hand, since IL-18 is structurally related to IL-1β and shares
some biological functions with IL-12 (Dinarello, 1999; Trinchieri,
1995), it is possible that IL-18 deficiency would have induced an
overcompensation of these two cytokines, which would then have been
responsible for the schizophrenic-like phenotype of IL-18KO mice. In
support of this hypothesis, we found increased levels of IL-1β and TNF-
α in brain regions of naïve IL-18KO mice. It was shown by others that
these animals also present increased IL-12 and IFN-γ levels in the hip-
pocampus in response to neurodegenerative processes in the brain
(Zhang et al., 2007). Accordingly, increased IFN-γ/IL-4 ratio, IL-1β and
IL-6 are observed in schizophrenic patients, which are normalized by
antipsychotic treatment (Kim et al., 2004; Miller et al., 2011). There-
fore, an overcompensation of other cytokines under specific circum-
stances could have contributed to the development of neuroimmuno-
logical processes and subsequent structural and/or functional brain
changes crucial for emotional regulation in IL-18KO mice.
Alternatively, IL-18 has also been suggested to mediate neuropro-
tective effects (Felderhoff-Mueser et al., 2005; Mori et al., 2001;
Sugama et al., 2004). In patients with schizophrenia, lower levels of
serum free IL-18 correlates with smaller hippocampal volume when
compared with healthy individuals. IL-18 can also influence brain
Fig. 3. Evaluation of aggressive behavior in IL-18KO mice. IL-18KO mice presented
higher aggressive-like behavior represented by A) lower latency to the first bite, B) a
tendency to increased number of attacks and C) increased total time of attacks and
compared to WT mice. Data are expressed as mean ± SEM. *p < 0.05 compared to WT
mice, Student t-test; n = 7–9/group.
Fig. 4. Behavior of IL-18KO mice submitted to the open field (A) forced swimming test
(B) or to the elevated plus maze (C). A) IL-18KO mice presented decreased distance
moved. *p < 0.05, Student t-test; n = 9/group. B and C) No significant effect in the
immobility time nor in the exploration of the open arms were observed. Student t-test;
n = 13 (WT) and 14 (KO) in the FST; 10 (WT) and 12 (KO) in the EPM. All data are
expressed as mean ± SEM.
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maturation processes (Felderhoff-Mueser et al., 2005) and, therefore, its
absence along brain development might have contributed to brain
changes responsible for the PPI deficit observed in IL-18KO mice.
Corroborating this hypothesis, the absence of other pro-inflammatory
cytokines, such as IL-1β, IL-6, and IL-2, during brain development was
shown to promote significant cytoarchitectural changes in regions re-
lated to the neurobiology of schizophrenia, such as the striatum and the
septo-hippocampal system (Parish et al., 2002; Petitto et al., 1999).
However, considering that IL-18 can exacerbate Th1 (IFN-γ related) or
Th2 (IL-4 related) responses depending on the cytokine milieu
(Nakanishi et al., 2001), the understanding of its role in schizophrenia
is still incomplete.
PPI has been widely used as a translational model of sensorimotor
gating ability. PPI disruption possibly reflects the difficulty of sup-
pressing or filtering excessive information in schizophrenic patients
(Braff et al., 2001, Swerdlow et al., 2008) and, therefore, PPI deficit has
been considered to reflect a schizophrenic-like phenotype across species
(Swerdlow et al., 2008). Accordingly, PPI is usually disrupted by drugs
that increase dopaminergic neurotransmission (Geyer et al., 2001). In
fact, dopamine appears to be very important in modulating PPI re-
sponse in laboratory animals and humans, acting, at least in part, in the
ventral striatum and frontal cortex (Bubser and Koch, 1994; Swerdlow
et al., 1990).
Besides being altered by drugs, PPI can also be altered by devel-
opmental, lesion or genetic manipulation (for review (Deslauriers et al.,
2013, Fone and Porkess, 2008, Jones et al., 2011). For instance, dis-
ruptions in brain development induced by genetic manipulation or in-
flammatory agents may lead to behavioral changes that correlate with
the positive symptoms of schizophrenia, such as increased hyperloco-
motion and dopamine release in the nucleus accumbens after amphe-
tamine (Flagstad et al., 2004; Fortier et al., 2004; Lipska et al., 1993;
Papaleo et al., 2012). In this scenario, the slight decrease of PPI re-
sponse found in the IL-18KO mice and its differential response to am-
phetamine treatment could be related to developmental alterations of
the dopaminergic system, probably due to the increased brain levels of
inflammatory cytokines, as we observed in the hippocampus and
medial prefrontal. Accordingly, maternal administration of poly I:C, a
toll-like receptor 3 (TLR3) agonist which mimics the acute phase of
viral infections (Meyer et al., 2006), induces alterations suggesting in-
creased dopaminergic sensitivity, and later stress-induced PPI deficits
(Deslauriers et al., 2013). These data suggest that increased in-
flammation during critical periods of brain development could alter
dopaminergic system and disrupt PPI in later life. Overall, our results
suggest that increased levels of some cytokines in IL-18KO mice brain
could assemble the neurodevelopment hypothesis of schizophrenia
(Brown, 2011; Fatemi and Folsom, 2009; Rapoport et al., 2012;
Weinberger, 1987).
Dopaminergic dysfunction is one of the main neurochemical hy-
potheses for schizophrenia (Carlsson and Lindqvist, 1963; Laruelle,
2013; Seeman, 2013). It is suggested that psychotic patients release
more dopamine after stimulation with amphetamine than normal in-
dividuals, suggesting increased midbrain dopaminergic activity (Abi-
Dargham et al., 2009). Our data with IL-18KO mice showing increased
hyperlocomotion after amphetamine treatment, therefore, suggest in-
creased midbrain dopaminergic activity in those animals, resembling
the positive symptoms of schizophrenia. At the dose used, amphetamine
by itself did not disrupt PPI in WT mice, but normalized PPI response in
IL-18KO mice, which could involve the hypodopaminergic prefrontal
cortex function (Laruelle, 2013; Laruelle and Abi-Dargham, 1999;
Seeman, 2013; Soares and Innis, 1999).
Social isolation, as used in the resident-intruder paradigm, is re-
ported to induce behavioral alterations, such as aggressiveness
(Chiavegatto and Nelson, 2003; Matsumoto et al., 2005), cognitive
deficits and impaired PPI in rodents. Both aggression and antisocial
behavior are observed in psychiatric disorders, including schizophrenia
(Buckley et al., 2011, Buckley et al., 2004, Serper, 2011, Soyka, 2011).
IL-18KO mice are more aggressive than their WT counterparts. In the
resident-intruder test, the latency for the first attack is considered an
index of reactivity or impulsivity, whereas the number and duration of
attacks would reflect aggression per se (Nelson et al., 1995; Zhuang
et al., 1999). We observed decreased latency and increased duration of
attacks, suggesting that absence of IL-18 confers higher impulsivity and
aggression. The dopaminergic system is activated when an offensive
animal meets a defensive one (Ferrari et al., 2003). Moreover, when-
ever a resident mouse encounters an aggressive intruder mouse,
Fig. 5. Behavior of IL-18KO mice submitted to repeated (5 days) forced swimming stress
in the elevated plus maze. A) Immobility time was evaluated in the first, third and fifth
day. No significant effect in the immobility time between IL-18KO and its wildtype (WT)
counterparts was observed (p > 0.05, Student t-test; n = 10–12/group). B) In the ele-
vated plus maze, repeated swimming stress decreased percentage of open arm entries and
there was a tendency of decreased percentage of time exploring these arms in IL-18KO
mice. Data are expressed as mean ± SEM. *p < 0.05 (Student t-test); n = 10 (WT) and
12 (KO).
Table 1
Evaluation of cytokine levels in the hippocampus (n = 7–9/group), in the medial prefrontal cortex (n = 6–8/group) or in the striatum of IL-18KO mice (n = 7–10/group). All data are
multiplied by 10−3. Data are given at pg/μg of total protein and expressed as mean ± SEM.
MPFC Striatum Hippocampus
WT IL-18 KO WT IL-18 KO WT IL-18 KO
IL-1β 5.8 ± 2.1 (n = 8) 18.6 ± 9.8 (n = 5) 3.4 ± 1.1 (n = 6) 18.6 ± 8.0 (n = 7) 4.3 ± 1.2 (n = 9) 19.7 ± 5.3* (n = 6)
IL-33 52.8 ± 14.4 (n = 10) 136.2 ± 73.3 (n = 7) 89.4 ± 26.1 (n = 10) 85.6 ± 37.6 (n = 7) 34.0 ± 7.6 (n = 9) 24.3 ± 4.1 (n = 7)
TNF-α 82.5 ± 6.2 (n = 8) 170 ± 40.7⁎ (n = 6) 112.5 ± 23.9 (n = 8) 106.6 ± 30.0 (n = 7) 97.1 ± 37.2 (n = 9) 78.7 ± 19.4 (n = 7)
⁎ p < 0.05, NS: non-significant.
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dopamine and other neurotransmitters increased in anticipation of the
confrontation (Narvaes, 2014). Therefore, this data strengthens the
proposition of high midbrain dopaminergic activity in IL-18KO mice. A
previous work showed that although polymorphisms in IL-18 gene do
not contribute to the susceptibility of schizophrenia in a Han Chinese
population, a single-nucleotide polymorphism in that gene was asso-
ciated with the presence of aggressive acts in the schizophrenic patients
(Liu et al., 2011). In addition, although to our knowledge there is no
work evaluating the direct involvement of IL-18 in aggressive behavior,
cytokine immunotherapy increase aggressive traits in patients, which
could be related to IL-1β (Pesce et al., 2011). This mechanism and the
possible involvement of a dopaminergic imbalance need to be further
investigated.
Regarding the participation of IL-18 in other stress-related psy-
chiatric disorders, recent studies have investigated the behavioral
phenotype of IL-18 null mice in different animal models. In line with
our results, IL-18KO mice with 5–7 weeks old exhibited a significant
deficit in the exploration of an open field (Yaguchi et al., 2010). Those
mice also exhibited normal acquisition but less retention of a fear
memory in the passive avoidance test (Yaguchi et al., 2010), suggesting
an anxiolytic-like effect as recently demonstrated (Too et al., 2014).
Older IL-18KO mice (12 weeks old), however, presented normal loco-
motor activity in the open field (Yamamoto et al., 2010). Although a
reduction in the open field can be interpreted as increased anxiety le-
vels, our results obtained with the EPM and previous one also using this
model (Yaguchi et al., 2010) or another animal model of anxiety
(Yamamoto et al., 2010) do not corroborate this idea. The different
results among these studies could be due to different ages or animal
background, with this latter factor being critical in the analysis of
complex behaviors (Crawley, 2008; Crusio et al., 2009). While the ge-
netic background of our IL-18KO mice is Balb/C, others have used
C57BL/6.
Contrasting results presented herein, a previous report showed that
IL-18KO mice presented decreased immobility time in the FST
(Yamamoto et al., 2010). In that study, however, the mice adapted to
the test on the next day, presenting immobility time similar to WT
(Yamamoto et al., 2010). These studies, however, used IL-18KO mice
with different genetic background. Another explanation for our nega-
tive results in the FST and EPM could be related to previous stress ex-
posure. Stress is able to regulate IL-18 expression in a glucocorticoid-
dependent way (Conti et al., 1997; Conti et al., 2000; Sekiyama et al.,
2005b; Sugama et al., 2000; Sugama et al., 2006) and IL-18 pattern of
expression during stress has suggested that this cytokine modulates
HPA axis activity in response to stress (Sekiyama et al., 2005a; Sugama
and Conti, 2008).Therefore, in the present study the fact that after re-
peated swimming stress IL-18KO mice presented anxiogenic behavior
support a role for IL-18 in controlling stress-induced HPA axis activa-
tion. Moreover, the increased stress-susceptibility in IL-18 null mice
could be mediated by its impact on microglia activation (Mori et al.,
2001, Sugama et al., 2004). These proposition, however, warrant fur-
ther investigation.
In conclusion, corroborating the suggestion that pro-inflammatory
cytokines are involved in the neurobiology of several psychiatric dis-
orders (Monji et al., 2009, Stone et al., 2008, Sugama and Conti, 2008,
Yaguchi et al., 2010), mice null for IL-18 presented increased levels of
specific cytokines in limbic brain regions, impaired sensorimotor
gating, increased sensitivity to amphetamine treatment, in addition to
increased aggressive behavior and sensitivity to stress exposure. This
knockout model, therefore, could provide new insights into how
changes in brain immunological homeostasis induce behavioral
changes related to psychiatric disorders such as schizophrenia.
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